Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United StatesP... by Yan Wang, Imad Al-Dakkak, Katherine Garlo, Moh-Lim Ong, Ioannis Tomazos, Arash Mahajerin

Get full text

Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry by Eric Rondeau, Spero R. Cataland, Imad Al-Dakkak, Benjamin Miller, Nicholas J.A. Webb, Daniel Landau, MD

Get full text

Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome by Anne-Laure Lapeyraque, Martin Bitzan, Imad Al-Dakkak, Mira Francis, Shih-Han S. Huang, Roger Kaprielian, Loree Larratt, Katerina Pavenski, Christine Ribic, Axel Tosikyan, Christoph Licht, David Philibert

Get full text